EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Broadly Protective Antibody‐Like Vaccines Against Highly Pathogenic Coronaviruses

Assala Helal, Najwa D Aljehani, Aishah Ghazwani iD, Reem M Alsulaiman, Faris Alyami, Wesam H Abdulaal, Asem Alsharef, Maimonah Alghanmi, Ayat Zawawi, Ala A Azhari, Afnan Almehmadi, Jood Balula und 9 weitere

Journal of Medical Virology · 2026-06 · 98 (6)

DOI: 10.1002/jmv.71008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 22.06.2026. Verfasst von Assala Helal und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Antibodies, Viral, SARS-CoV-2, Middle East Respiratory Syndrome Coronavirus, COVID-19 Vaccines. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jameel Fund for Infectious Disease Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS‐CoV‐2 and MERS‐CoV are highly pathogenic and contagious coronaviruses. Despite intensive vaccination, SARS‐CoV‐2 continues to spread, and no FDA‐approved vaccines exist for MERS‐CoV; thus, more effective and safer vaccine options are needed. The receptor‐binding domain (RBD) of coronaviruses is a primary target of neutralizing antibodies (nAbs); therefore, we generated three bivalent IgG1 Fc‐fusion vaccines (BiVaxs) combining SARS‐CoV‐2 and MERS‐CoV RBDs. The BiVax Fc‐Native vaccine comprises omicron's‐RBD SARS‐CoV‐2 fused to the native Fc C‐terminus and RBD MERS‐CoV to the N‐terminus. The BiVax Fc‐Reverse vaccine has a native Fc, yet RBD MERS‐CoV was fused to the C‐terminus, and the omicron's‐RBD SARS‐CoV‐2 to the N‐terminus. The third was BiVax Fc‐FcRn , which is similar to BiVax Fc‐Native , although it contains MST‐HN Fc mutations (M252Y/S254T/T256E‐H433K/N434F) to enhance neonatal Fc receptor (FcRn) binding on antigen‐presenting cells (APCs). In mice, BiVax Fc‐FcRn showed significantly higher immunogenicity than the other two forms. It induced robust IgG and nAb responses against RBD MERS‐CoV after two doses and moderate responses omicron's‐RBD SARS‐CoV‐2 after the third dose. Remarkably, it also generated strong cross‐reactive antibodies against SARS‐CoV‐1. These findings suggest that RBD MERS‐CoV is more immunogenic than omicron's‐RBD SARS‐CoV‐2, and that BiVax Fc‐FcRn has a high potential for further development as a broad‐spectrum vaccine platform to prevent infection with the targeted coronaviruses as well as future emerging viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralSARS-CoV-2Middle East Respiratory Syndrome CoronavirusCOVID-19 VaccinesCOVID-19Viral VaccinesAnimalsMiceAntibodies, NeutralizingHumansImmunoglobulin GSpike Glycoprotein, CoronavirusFemaleSevere acute respiratory syndrome-related coronavirusVaccines, Synthetic

Stichwörter der Autor:innen

Fc‐fusionMERS‐CoVSARS‐CoV‐2antibodiescoronavirusesvaccines

Substanzen

Antibodies, ViralAntibodies, NeutralizingImmunoglobulin GSpike Glycoprotein, CoronavirusCOVID-19 VaccinesViral VaccinesVaccines, Synthetic

Autor:innen und Institutionen

  • Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.

ORCID-Profile: Aishah Ghazwani, Tarfa Altorki, Khalid Alluhaybi, Turki S Abujamel, Anwar M Hashem

Förderung

  • Jameel Fund for Infectious Disease Research and Innovation

Zitieren

APA

Helal, A., Aljehani, N. D., Ghazwani, A., Alsulaiman, R. M., Alyami, F., Abdulaal, W. H., Alsharef, A., Alghanmi, M., Zawawi, A., Azhari, A. A., Almehmadi, A., Balula, J., Altorki, T., Alhabbab, R. Y., Khan, M. Y., Alluhaybi, K., Alnami, A., Neamatallah, T., Abujamel, T. S., …, & Hashem, A. M. (2026). Broadly Protective Antibody‐Like Vaccines Against Highly Pathogenic Coronaviruses. Journal of Medical Virology, 98(6). https://doi.org/10.1002/jmv.71008

Vancouver

Helal A, Aljehani ND, Ghazwani A, Alsulaiman RM, Alyami F, Abdulaal WH, et al. Broadly Protective Antibody‐Like Vaccines Against Highly Pathogenic Coronaviruses. Journal of Medical Virology. 2026;98(6). doi:10.1002/jmv.71008

BibTeX
@article{Helal2026,
  author = {Helal, Assala and Aljehani, Najwa D and Ghazwani, Aishah and Alsulaiman, Reem M and Alyami, Faris and Abdulaal, Wesam H and Alsharef, Asem and Alghanmi, Maimonah and Zawawi, Ayat and Azhari, Ala A and Almehmadi, Afnan and Balula, Jood and Altorki, Tarfa and Alhabbab, Rowa Y and Khan, Muhammad Yasir and Alluhaybi, Khalid and Alnami, Aisha and Neamatallah, Thikryat and Abujamel, Turki S and Alfaleh, Mohamed A and Hashem, Anwar M},
  title = {Broadly Protective Antibody‐Like Vaccines Against Highly Pathogenic Coronaviruses},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {6},
  doi = {10.1002/jmv.71008}
}
Kostenlos starten →